Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

RNA-Based Therapies Targeted In Two Deals

by Ann M. Thayer
January 19, 2009 | A version of this story appeared in Volume 87, Issue 3

Cubist Pharmaceuticals and Alnylam Pharmaceuticals will work together to advance therapies to treat respiratory syncytial virus (RSV) infections. Cubist will pay Alnylam $20 million up front, as well as potential milestone payments that could total $82.5 million. Included is ALN-RSV01, an RNAi-based RSV inhibitor in Phase II trials for lung transplant patients. Separately, Wyeth is working with Denmark's Santaris Pharma to develop therapies based on Santaris' locked nucleic acid technology, which generates inhibitors of micro and messenger RNAs. Along with a $10 million equity investment, Wyeth will pay Santaris $7 million in cash and potential payments of up to $83 million for each of 10 targets.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.